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Background-—Cardiomyopathies are heterogeneous diseases with clinical presentations varying from asymptomatic to life-
threatening events, including severe heart failure and sudden cardiac death. The role of underlying genetic and disease-modulating
factors in children and adolescents is relatively unknown. In this prospective study, in-depth phenotypic and genetic
characterization of pediatric patients with primary cardiomyopathy and their first-degree family members (FMs) was performed.
Outcome was assessed to identify clinical risk factors.
Methods and Results-—Sixty index patients with primary cardiomyopathy (median age: 7.8 years) and 124 FMs were enrolled in the
RIKADA (Risk Stratification in Children and Adolescents with Primary Cardiomyopathy) study. Family screening included cardiac
workup and genetic testing. Using cardiologic screening, we identified 17 FMs with cardiomyopathies and 30 FMs with suspected
cardiomyopathies. Adverse events appeared in 32% of index patients and were more common in those with lower body surface area
(P=0.019), increased NT-proBNP (N-terminal pro–brain natriuretic peptide; P<0.001), and left ventricular dysfunction (P<0.001) and
dilatation (P=0.005). The worst prognosis was observed in dilated and restrictive cardiomyopathies. Genetic variants of interest were
detected in patients (79%) and FMs (67%). In all 15 families with at least 1 FM with cardiomyopathy, we found a variant of interest in
the index patient. Increased number of variants of interest per patient was associated with adverse events (P=0.021). Late gadolinium
enhancement was related to positive genotypes in patients (P=0.041).
Conclusions-—Lower body surface area, increased NT-proBNP, left ventricular dysfunction or dilatation, late gadolinium
enhancement, and increased number of variants of interest were associated with adverse outcome and should be considered for
risk assessment in pediatric primary cardiomyopathies.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identifier: NCT03572569. ( J Am Heart Assoc. 2019;8:
e012531. DOI: 10.1161/JAHA.119.012531.)
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C ardiomyopathies are a heterogeneous group of myocar-dial diseases, especially in the pediatric population.
Dilated cardiomyopathy (DCM) and hypertrophic cardio-
myopathy (HCM) are the most common; restrictive
cardiomyopathy (RCM), left ventricular noncompaction car-
diomyopathy (LVNC), and mixed cardiomyopathies occur
infrequently; and arrhythmogenic right ventricular cardiomy-
opathy (ARVC) is rare.1 According to the American Heart
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Association, cardiomyopathies are associated with mechan-
ical and/or electrical dysfunction and are classified into
primary (genetic, nongenetic, acquired) and secondary
forms.2 The European Society of Cardiology groups car-
diomyopathies as DCM, HCM, RCM, ARVC, and unclassified,
including LVNC. Further subclassification into familial/
genetic and nonfamilial/nongenetic forms is proposed.3 In
the current literature, overall incidence of cardiomyopathies
of 1.13 per 100 000 children is reported.4 Severe pediatric
cardiomyopathy has a peak age of diagnosis of <1 year.4,5
Children with cardiomyopathies often present with heart
failure signs, and, accordingly, therapeutic regimens are
mostly symptomatic.6–8 Mechanical circulatory support
(MCS) or heart transplantation (HTx) is often required,
particularly in DCM patients with progression of heart
failure.9 Due to arrhythmia, syncope, or sudden cardiac
death, patients with HCM frequently receive an implantable
cardioverter-defibrillator.10
Mutations in sarcomere genes are commonly found in
adults and children with cardiomyopathies.1,11–14 Genetic
causes of DCM are the most heterogeneous, with alterations
also involving desmosomal, cytoskeletal, and mitochondrial
genes.15 Results of genetic testing require careful interpre-
tation according to the individual patient context and family
history. Clinical screening for cardiomyopathies is recom-
mended in asymptomatic, at-risk, first-degree family members
(FMs). If genetic testing is positive in the index patient,
cascade genetic testing of FMs is recommended for risk
assessment.16
There is a need to characterize pediatric patients who are
at risk for development of heart failure and adverse events so
as to enable family counseling and to generate individual
diagnostic and therapy regimens.17 In this prospective study,
systematic pheno- and genotype characterization in pediatric
patients with primary cardiomyopathies and their first-degree
FMs was performed with a focus on identifying clinical risk
factors.
Methods
Data
To minimize the possibility of unintentionally sharing infor-
mation that can be used to reidentify private information, a
subset of the data generated for this study is available in the
ClinVar database.18
Study Population
Patients aged ≤18 years with a diagnosis of primary car-
diomyopathies and their first-degree FMs including siblings
and parents were prospectively enrolled in the RIKADA (Risk
Stratification in Children and Adolescents with Primary
Cardiomyopathy) study between February 2014 and January
2017 at the Charite-Universit€atsmedizin Berlin and the
German Heart Center Berlin in Berlin, Germany.
The following inclusion criteria were used: DCM indicated
by left ventricular (LV) systolic dysfunction and dilatation >2
SD above the mean of a normal population19; HCM indicated
by LV hypertrophy and septal wall thickness >2 SD10,19; RCM
indicated by diastolic dysfunction and concordant atrial
enlargement20; LVNC shown by separation of the myocardium
into compacted and noncompacted layers with a noncom-
pacted/compacted ratio >2 at transthoracic echocardiogra-
phy (TTE)21 and/or >2.3 at cardiovascular magnetic
resonance (CMR)22; and ARVC based on the revised task
force criteria.23. In adults, TTE reference values for LV end-
diastolic diameter, septal thickness, and ejection fraction (EF)
were chosen according to Lang et al,24 and CMR reference
values for ventricular dimensions were chosen according to
Hudsmith et al,25 considering values beyond the reference
limits as abnormal. The clinical diagnosis of HCM was based
on the presence of otherwise unexplained increase in LV wall
thickness ≥13 mm in ≥1 LV myocardial segment, as
measured using TTE or CMR.10
Suspected cardiomyopathies in FMs were defined as
follows: hypertrabeculation with a noncompacted/compacted
ratio <2 in TTE and/or <2.3 in CMR, mildly reduced LV
systolic function (EF 50–54%) at TTE and/or CMR, borderline
or mildly increased LV end-diastolic diameter at TTE and/or
LV end-diastolic volume at CMR, or mildly increased septal
Clinical Perspective
What Is New?
• This prospective study highlights parameters for adverse
outcome in primary pediatric cardiomyopathy over a variety
of phenotypes.
• Adverse events occur in nearly a third of the index patients,
and patients with dilated and restrictive cardiomyopathies
have the worst prognosis.
• With systematic family screening, hypertrabeculated myo-
cardium is the most frequently occurring cardiac abnormal-
ity found in family members.
What Are the Clinical Implications?
• Systematic phenotype and genotype characterization pro-
vides important prognostic information in children and
adolescents with primary cardiomyopathy.
• Long-term multicenter studies are needed to ascertain the
underlying genetic and disease-modulating factors in chil-
dren and adolescents.
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thickness and/or myocardial crypts at TTE and/or CMR.
Individuals with evidence of myocardial inflammation or
myocarditis, systemic disease with cardiac involvement, or
structural congenital heart disease were excluded. Within
family screening, complete cardiac workup and genetic
testing were performed in index patients and both clinically
affected and unaffected FMs (Figure 1).
The study was approved by the institutional ethics
committee (Charite-Universit€atsmedizin Berlin) in accordance
with the Declaration of Helsinki, and all participants and
parents or guardians of patients <18 years gave written
informed consent.
Follow-Up
The occurrence of adverse events since the date of
cardiomyopathy diagnosis including MCS, HTx, and all-cause
death, including sudden cardiac death, was noted from
medical records and defined as a combined end point.
Laboratory and Genetic Testing
A standard laboratory testing including NT-proBNP (N-terminal
pro–brain natriuretic peptide) was applied. Genetic screening
was performed with next-generation sequencing for genetic
variants in 174 target genes (Illumina TruSight Cardio
Sequencing Panel).26 A total of 89 cardiomyopathy genes
were bioinformatically filtered with a minor allele frequency of
<0.001 (gnomAD reference database, https://gnomad.b
roadinstitute.org/) and classified according to the guidelines
of the American College of Medical Genetics and Genomics
(ACMG; Table S1).27 Each detected variant was validated (as
of November 30, 2017) with databases displaying genetic
variants for cardiomyopathy: Human Gene Mutation Database
(http://www.hgmd.cf.ac.uk/ac/index.php), Exome Variant
Server (http://evs.gs.washington.edu/EVS/) and the Atlas
of Cardiac Genetic Variation (https://cardiodb.org/ACGV/).
Genetic variants of interest (VOIs) included variants of
unknown significance (VUSs), likely pathogenic and patho-
genic variants. Genetic data were analyzed with regard to
genotype positivity (detection of VOI), grade of pathogenicity
(VUS, likely pathogenic; or pathogenic) and number of VOI
(Figure S1). Patients were classified as genetic if they had a
VOI and as sporadic if they had no VOI or a family history of
cardiomyopathy. No VOI but positive family history of
cardiomyopathy was seen in only 1 index patient who was
thus excluded from the Kaplan–Meier analysis. An index
patient was categorized as having familial cardiomyopathy if a
cardiomyopathy was present in at least 1 first-degree FM.
Novel VOIs will be deposited in the ClinVar database (https://
www.ncbi.nlm.nih.gov/clinvar/).18
Cardiopulmonary Exercise Testing
Symptom-limited cardiopulmonary exercise testing under strict
monitoring of signs of ischemia and arrhythmia was performed
on a treadmill ergometer in adherence to the protocol of the
German Society of Pediatric Cardiology, and data were
compared with reference values for children and adults.28
Echocardiography
Detailed TTE, considering cardiac morphology, dimensions,
and systolic and diastolic function, was conducted at rest, and
offline analyses were carried out by 2 independent observers
(N.A.M., F.D.) according to the recommendations for adults
and children.24,29
Cardiovascular Magnetic Resonance
All CMR studies were performed at 1.5 T, using a standardized
protocol with acquisition of images in short and long axis and
axial orientation to allow for detailed morphologic and functional
analyses andmyocardial tissue characterization. Late gadolinium
enhancement (LGE) images were acquired after bolus adminis-
tration of gadolinium-DOTA (Dotarem; Guerbet). Siblings aged
≤18 years underwent CMR when sedation was not necessary.
Statistical Analyses
Categorical variables are summarized by frequencies and
percentages. For continuous measures, data are presented as
median values and interquartile ranges. The Fisher exact test
Figure 1. Study design. The protocol of the RIKADA (Risk
Stratification in Children and Adolescents with Primary Cardio-
myopathy) study involved in-depth family screening of 60
pediatric index patients and all available first-degree family
members (FMs). CMR was performed in index patients and FMs,
including siblings aged ≤18 years, for preclinical detection of
cardiomyopathy. CMR indicates cardiovascular magnetic reso-
nance; CPET, cardiopulmonary exercise testing; TTE, transthoracic
echocardiography.
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was used to compare dichotomous variables in tables with
expected cell frequencies of <5; otherwise, the Pearson v2
test was performed. For comparison of 2 and ≥2 independent
groups, the Mann-Whitney U test and the Kruskal-Wallis test
were applied, respectively. Survival analysis was performed
with the Kaplan–Meier method to estimate the probability of
survival in all index patients and to compare survival
distributions of different groups, defining time at diagnosis
as time point 0. Overall differences between estimated
survival curves of ≥2 groups were assessed with the log-rank
test. The Kaplan–Meier method, a nonparametric estimator of
the survival function, is widely used to estimate and graph
survival probabilities as a function of time. It can be used to
obtain univariate descriptive statistics for survival data,
including median survival time, and compare the survival
experience for ≥2 groups of participants. To test for overall
differences between estimated survival curves of ≥2 groups of
participants, such as between different cardiomyopathy
subgroups or genetic versus sporadic cardiomyopathies,
several tests are available, including the log-rank test. This
can be performed as a type of v2 test, a method for comparing
the Kaplan–Meier curves estimated for each group of partic-
ipants. A probability value <0.05 is considered statistically
significant. Data were analyzed with SPSS v24.0 (IBM Corp).
Results
Family Screening
Sixty index patients with a median age of 7.8 years were
enrolled (35 male, 25 female; Table S2). Diagnoses included
21 DCM, 17 HCM, 15 LVNC, 5 RCM, and 2 ARVC. In total, 124
FMs were enrolled (Figure 2). This group comprised 25
siblings aged ≤18 years (median: 10.6 years), 8 siblings aged
>18 years (median: 19.6 years), and 91 parents (median age:
40.0 years; Tables S3 and S4). Family screening of 60
families identified cardiomyopathies in 17 of 124 FMs. In 11
of 124 FMs, cardiomyopathies had been diagnosed before
study enrollment. In addition, clinical screening in this study
revealed cardiomyopathies in 6 of 124 FMs, and in 2 families,
2 FMs were affected; therefore, family screening showed
cardiomyopathies in 15 of the 60 screened families (25%;
Figure 2). A positive family history was present in 36% of
families.
Of 57 index patients, 45 (n=79%) had at least 1 genetic
VOI, and 12 index patients had none. In the index patients, 1
VOI was found in 39% and >1 VOI was found in 40%. Of all
genotype-positive index patients, classification according to
the highest grade of pathogenicity revealed pathogenic VOIs
in 18 (40%), likely pathogenic VOIs in 16 (36%), and VUSs in
Figure 2. Clinical diagnosis and genetic information in the family context. For the RIKADA (Risk Stratification in Children and Adolescents with
Primary Cardiomyopathy) study, 60 index patients and 124 family members (FMs) were enrolled. These 60 families were classified according to
their clinical diagnosis of the first-degree FM either as family with cardiomyopathy (group 1), family with a suspected cardiac phenotype (group
2), or as family without detection of any cardiovascular signs (group 3). In families with a suspected cardiac phenotype, we most frequently
observed left ventricular hypertrabeculation. Overall, 57 of 60 index patients underwent genetic testing. The genetic information was
implemented by counting the highest graded VOIs in each family. Families with a de novo VOI were listed as families without cardiovascular
signs. In 12 families, we did not detect any VOI. CMP indicates cardiomyopathy; VOI, variant of interest; VUS, variant of unknown significance.
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11 (24%). DNA was not available for 3 index patients, and
family screening was not performed for 2 adopted children.
Consequently, 45 index patients had genetic cardiomy-
opathies, 10 had sporadic cardiomyopathies, and 5 remained
undetermined. In 26 of 45 (58%) index patients with VOIs,
family history was negative for cardiomyopathies. Only 1
patient had a positive family history with a negative genotype.
Identification of at-risk relatives with cardiologic
screening
CMR images in Figure 3A highlight typical cardiomyopathy
phenotypes for DCM, HCM, LVNC, and ARVC. Of the 17 FMs
diagnosed with a cardiomyopathy, 4 had DCM, 5 had LVNC, 5
had HCM, and 3 had RCM. Fourteen FMs had the same
phenotype as the index patient in the family.
With cardiologic screening, we identified 30 FMs with
suspected cardiomyopathies. Nineteen had hypertrabecu-
lation without LVNC (Figure 3B), 4 had mildly reduced
LVEF, 3 had borderline or mildly increased LV dimensions,
3 had mildly increased interventricular septum thickness,
and 1 had biventricular enlargement and hypertrabecula-
tion. Hypertrabeculation was the most frequently found
cardiac abnormality in FMs. Twenty of the 30 FMs
with suspected cardiomyopathies had genetic testing
and 16 had VOIs, of which 9 were likely pathogenic or
pathogenic.
Figure 3. Cardiovascular magnetic resonance (CMR) in pediatric primary cardiomyopathy. A, CMR images highlight typical cardiomyopathy
phenotypes for DCM, HCM, LVNC, and ARVC. Cine (upper row) and corresponding LGE (lower row) images are presented. Red arrows indicate
regions with positive LGE. B, Hypertrabeculation is shown for individual 1-II:1 in short-axis, 2-, 3- and 4-chamber views (yellow arrows). ARVC
indicates arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LGE, late
gadolinium enhancement; LVNC, left ventricular noncompaction cardiomyopathy.
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At least 1 FM with suspected cardiomyopathy was
identified in 17 families, and 28 families were without any
FM who was affected or had suspected cardiomyopathy
(Figure 2). In all families with a least 1 FM with cardiomy-
opathy, we found a VOI in the index patient (15/15). In the 17
families including at least 1 additional FM with suspected
cardiomyopathy, a VOI was found in 11 index patients. In 28
of 60 families with cardiomyopathies that had no further FM
with cardiomyopathy or suspected cardiomyopathy, a VOI was
present in 19 of the 28 index patients.
Genetic-variant burden in FMs
We used targeted sequencing in 45 families to test 90 FMs
for the VOI previously identified in the index patient
(Figure 2). At least 1 VOI was detected in 60 individuals
(67%). Among the genotype-positive FMs, we identified 1 VOI
in 67% and >1 VOI in 33%. Of all genotype-positive FMs,
classification according to the highest grade of pathogenicity
revealed the following distribution of VOIs: pathogenic in 13
of 60 (22%), likely pathogenic in 19 of 60 (32%), and VUSs in
28 of 60 (47%).
Clinical and Genetic Characteristics of Index
Patients
DCM and RCM patients presented with higher New York Heart
Association classes (P=0.047), increased frequencies of heart
failure symptoms (P<0.001), elevated NT-proBNP levels
(P=0.073), and reduced maximum oxygen consumption
(P=0.337; Figure 4 and Table S2). TTE revealed the most
severe LV dysfunction (P<0.001) and dilatation (P<0.001) in
patients with DCM. Positive LGE was associated with a
positive genotype (P=0.041). All 8 patients with positive LGE
had a positive genotype.
CMR was performed in 8 HCM patients. Positive LGE at
CMR was present in 4 of 8 of the HCM patients. In those, NT-
proBNP levels (P<0.001) and E/E0 at TTE (P=0.019) were
elevated, and LV hypertrophy was pronounced with greater
interventricular septum diastolic diameter Z scores at TTE
(P=0.038) and indexed LV mass at CMR (P=0.002) than in
HCM patients with negative LGE.
At Holter ECG, arrhythmias including supraventricular and
nonsustained ventricular tachycardias occurred with low
Figure 4. Clinical characterization of index patients and family members. Clinical information for all study
individuals is presented in absolute values for each subgroup. Heart failure was defined as acute right or left
heart failure with peripheral edema and/or pulmonary congestion. Arrhythmias included supraventricular
and nonsustained ventricular tachycardia and were recorded with Holter ECG. MACE summarizes
mechanical circulatory support, heart transplantation, and death. Values for arrhythmogenic right
ventricular cardiomyopathy (n=2) are not presented. Of note, 4 of 8 HCM patients tested LGE positive. The
full clinical information for each group is available in Tables S2 through S5. The sample size value indicates
the number of analyzed individuals for a given parameter. CMR indicates cardiovascular magnetic
resonance; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; IQR, interquartile range;
LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; LVNC, left ventricular
noncompaction cardiomyopathy; MACE, major adverse cardiovascular events; NT-proBNP, N-terminal pro–
brain natriuretic peptide; RCM, restrictive cardiomyopathy.
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frequency (7/43 index patients). An association between
arrhythmia and LGE from CMR was not seen. Arrhythmias and
signs of ischemia were not observed during cardiopulmonary
exercise testing. Clinical characteristics of index patients are
summarized in Table S2.
Six patients received an implantable cardioverter-defibril-
lator for prevention of sudden cardiac death, 5 of them for
primary prevention. No appropriate implantable cardioverter-
defibrillator shocks were recorded. Ten patients needed MCS
with a ventricular assist device, and 3 patients received
extracorporal membrane oxygenation and a ventricular assist
device. Fifteen patients underwent HTx, of which 1 RCM
patient had combined HTx and lung transplantation. Two
children with RCM died. In one, the cause of death was sepsis
with multiple organ failure; the other had sudden cardiac
death 3 months after HTx (Table S3). The detection rate for
>1 VOI was significantly higher in HTx patients than in non-
HTx patients (P=0.011).
The clinical characteristics of FMs as part of the family
screening are depicted in Figure 4 and Tables S4 and S5.
Follow-Up of Index Patients
No patient was lost to follow-up. During a median follow-up of
2.9 years (range: 1.2-6.9 years), adverse events occurred in
32% of the index patients (Table S3; Figure 5A). The combined
end point was more common in children with lower body
surface area (BSA; P=0.019), increased NT-proBNP (P<0.001),
reduced LVEF (TTE: P<0.001; CMR: P=0.062), and LV
dilatation (TTE: LV end-diastolic diameter Z scores, P=0.005;
CMR: indexed LV end-diastolic volume, P=0.005).
Event-free survival was significantly different between car-
diomyopathy subgroups regarding death (P<0.001), HTx
(P=0.002), MCS (P=0.012), and the combined end point
(P<0.001). Prognosis was worst in patients with RCM and
DCM (Table S3; Figure 5B). Age at diagnosis (P=0.276) and sex
(P=0.282) had no significant impact on the combined end point.
Survival analysis showed that the probability of adverse
events was significantly higher in patients with >1 VOI
compared with those with 1 or no VOI (P=0.021; Figure 5C).
Patients with sporadic cardiomyopathies had fewer adverse
events than those with genetic cardiomyopathies, albeit
without a statistically significant difference (P=0.305; Fig-
ure 5D). The event-free rate for the combined end point was
not significantly affected by genotype positivity (P=0.441),
grade of pathogenicity (P=0.893), or family history (familial vs.
nonfamilial cardiomyopathy, P=0.365).
Familial Segregation
The clinical courses of family 1 (Figure 6A) and family 2
(Figure 6B) were remarkable because of infant cardiomyopathy
requiring HTx in the index patients. In both families, the severe
phenotypes of LVNC and DCM, respectively, were caused by a
double VOI; one was de novo, and one was inherited from a
parent. In family 1, a de novo pathogenic variant in ACTN2
(a-actinin 2) produces a stop codon at amino acid position 192,
which leads to premature truncation of the protein. In addition,
a VUS (p.Gly142Val) in MYLK2 (myosin light chain kinase 2)
was detected in the clinically asymptomatic father and in the
index patient. The father was grouped as suspected cardiac
phenotype because of LV hypertrabeculation that did not fulfill
the criteria for LVNC (individual 1-I:1; Figure 3B). In family 2,
another MYLK2-likely pathogenic missense variant, p.Ala2Thr,
was found in the index patient and his clinically asymptomatic
mother, who presented with LV hypertrabeculation on CMR. A
likely pathogenic ACTC1 (a-cardiac actinin) missense variant,
p.Ala110Thr, occurred de novo in the index patient of family 2.
In family 3 (Figure 6C), an X-chromosomal inheritance
pattern with a likely pathogenic hemizygous variant occurred
in the male index patient. He was diagnosed with LVNC as an
infant and had inherited the variant in TAZ (taffazin),
Val119Met, from his mother. Cardiologic screening of the
mother (individual 3-I:1) was unremarkable except for the
presence of LV hypertrabeculation on CMR. In the index
patient, clinical evaluation showed no evidence of Barth
syndrome but isolated LVNC.
Family 4 (Figure 6D) represents an example of a family
with an index patient requiring HTx during infancy because of
DCM and early detection of cardiomyopathy in a FM. Through
the study, the clinically asymptomatic father (individual 4-I:1)
was diagnosed with LVNC with reduced biventricular EFs on
CMR (LVEF: 52%; right ventricular EF: 48%) and echocardio-
graphy (LVEF: 44%) but normal ventricular dimensions. Two
likely pathogenic variants were present in the index patient
and his father, in TPM1 (a-tropomyosin), p.Glu114Gln, and in
PKP2 (plakophilin 2), p.Asn512Lys.
Two affected FMs of family 5 (Figure 6E), the 15-year-old
index patient and her mother, presented with LVNC. Individual
5-II:1 was asymptomatic and diagnosed because of family
screening, initiated because her mother had known symp-
tomatic LVNC with palpitations but normal LV dimensions and
LVEF. The mother and the index patient carried the likely
pathogenic variant in MYH7 (b-myosin heavy chain),
P.Ala428Asp. In addition, the index patient inherited the likely
pathogenic variant p.Thr602Ile in MYBPC3 (cardiac myosin-
binding protein C) from her unaffected father. Her LVEF
deteriorated during the 3-year study period from 55% to 45%,
which required medication with an angiotensin-converting
enzyme inhibitor and a b-blocker and closer follow-up intervals.
In family 6 (Figure 6F), a pathogenic splice-site variant in
MYBPC3, c.927-2A>G, and a likely pathogenic missense
variant p.Cys598Arg in LDB3 (LIM domain-binding 3) was
identified in the 17-year-old index patient with HCM. Both
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variants were also present in his father (individual 6-I:1) and his
brother (individual 6-II:3), who was 9 years old at the time of
study enrollment. Individual 6-I:1 was known to have HCM and
had an implantable cardioverter-defibrillator implanted at age 29.
Individual 6-II:3 had extended crypts/hypertrabeculation on the
initial study CMR. Individual 6-II:1, the 19-year-old sister of the
index patient, was heterozygous for theMYBPC3 variant only and
was suspected to have HCM with an interventricular septal
thickness at end-diastole of 10 mm, but diagnostic criteria were
fulfilled only by CMRwithmidventricular septal hypertrophy. This
family exemplifies that different imaging modalities need to be
combined in the evaluation of FMs for presymptomatic detection
of affected status.
Discussion
Within this prospective study, we systematically analyzed
the phenotypes of pediatric patients with primary cardiomy-
opathies and their first-degree FMs, complemented by
genetic analysis. Lower BSA, increased NT-proBNP, LV
dysfunction and dilatation, LGE, and increased number of
VOIs were associated with adverse outcome. Adverse
Figure 5. Adverse events in index patients with cardiomyopathy. Kaplan–Meier curves illustrate the
event-free survival to the combined end point of death, heart transplantation, and mechanical circulatory
support: (A) in all index patients, (B) between the different cardiomyopathy subgroups DCM, HCM, LVNC,
RCM, and ARVC, (C) with regard to the absolute number of VOIs, and (D) in genetic vs sporadic
cardiomyopathy. No VOI but positive family history of cardiomyopathy was seen in only 1 index patient who
was thus excluded from the Kaplan–Meier analysis. ARVC indicates arrhythmogenic right ventricular
cardiomyopathy; CMP, cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy;
LVNC, left ventricular noncompaction cardiomyopathy; RCM, restrictive cardiomyopathy; VOI, variant of
interest.
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events occurred in nearly a third of the index patients, and
DCM and RCM patients had the worst prognoses. VOIs in
cardiomyopathy genes were frequently observed in both
index patients and FMs (79% and 67%, respectively). Family
screening suggests a large load of uncertain genetic
variants in FMs or possibly nonpenetrance of pathogenic
variants, which needs more long-term follow-up to verify. In
60 families, screening identified 15 families with cardiomy-
opathies (group 1) and 17 with a suspected cardiac
phenotype (group 2). In all 15 families with an index
patient and at least 1 FM with cardiomyopathy, we found a
VOI in the index patient, suggesting strong penetrance of
the VOI in group 1. Hypertrabeculated myocardium was the
most frequently found cardiac abnormality in FMs and was
observed in 20 of the 30 FMs with a suspected cardiac
phenotype. In 11 of 17 FMs with a suspected cardiac
phenotype, we identified a VOI. It is assumed that there is a
continuum from normal, hypertrabeculated myocardium to
pathological appearance of the LV myocardium.30 We
speculate that the VOIs in group 2 are less penetrant and
lead to a subclinical phenotype such as hypertrabeculation.
Our study supports that clinical and genetic information of
index patients and FMs may predict phenotypes in
relatives.31
Figure 6. Pedigrees of RIKADA (Risk Stratification in Children and Adolescents with Primary Cardiomyopathy) study families. A through F, The
affected individuals of the selected families demonstrate with LVNC, DCM, or HCM (black-filled symbols). Family members may present without
cardiomyopathy but with a suspected cardiac phenotype (gray symbols). Detected VOIs are given for each family member. In families 1 and 2,
VOI2 is a de novo variant. DCM indicates dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HTx, heart transplant; LVNC, left
ventricular noncompaction cardiomyopathy; VOI, variant of interest. ACTC1, actin, alpha, cardiac muscle 1; ACTN2, actinin alpha 2; CBL, CBL
proto-oncogene; EYA4, EYA transcriptional coactivator and phosphatase 4; LDB3, LIM domain binding 3; MYBPC3, myosin binding protein C,
cardiac; MYH7, myosin heavy chain 7; MYLK2, myosin light chain kinase 2; PKP2, plakophilin 2; TAZ, tafazzin; TPM1, tropomyosin 1.
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Clinical signs of heart failure and imaging measures of LV
dysfunction (LVEF) and dilatation (TTE: LV end-diastolic
diameter Z scores; CMR: indexed LV end-diastolic volume)
were associated with adverse outcomes. This result is in line
with previous reports of children with HCM and DCM in whom
congestive heart failure and severity of LV dysfunction were
identified as predictors of death or HTx.8,32 Published data on
survival in pediatric cardiomyopathies have shown rather
conflicting results regarding the impact of age. The above-
mentioned studies on HCM and DCM also found younger age
and decreased weight and body mass index to be risk factors
for adverse outcome; however, in a study from the Pediatric
Cardiomyopathy Registry comparing the survival of children
with familial DCM with that of children with idiopathic DCM,
older age was associated with an increased risk of death or
HTx.33 Alexander et al detected worse survival in DCM
patients diagnosed at <4 weeks and >5 years of age.34 In a
study of pediatric HCM, the poorest prognosis was seen in
patients presenting <1 year of age; however, in those
surviving beyond age 1, survival was independent of the age
at diagnosis.35
In our study, age at diagnosis had no significant impact on
the combined end point, but lower BSA did. Age at diagnosis
is commonly the time when clinical symptoms occur, and this
can be variable in children.4,19 Lower BSA indicated that
younger children with lower weight in this study were at
higher risk for adverse events.
LGE at CMR reflects focal myocardial fibrosis and has been
described as a substrate for arrhythmia and adverse outcome
in adult cardiomyopathies.36 Comparatively little is known
about the prevalence and clinical relevance of LGE in pediatric
cohorts, and data are mainly limited to HCM.37,38 In our study,
LGE was positive in almost 30% of the index patients, with a
prevalence of 50% in HCM, 18% in DCM, and 17% in LVNC
patients. Comparable prevalences of 46–52% were detected
in larger pediatric HCM cohorts.37,38 We found positive LGE in
the HCM subgroup to be associated with more pronounced LV
hypertrophy and with clinical and imaging markers of heart
failure and LV diastolic dysfunction, pointing to LGE as a risk
factor in pediatric HCM. An increase of LGE over time has
been described in both pediatric and adult HCM, underscoring
the importance of serial CMR imaging to monitor disease
progression.38,39 In this study, arrhythmias occurred at much
lower frequency than would be expected from the percentage
of LGE-positive patients, especially in the HCM subgroup, with
no association between arrhythmias and LGE. This may be
explained by the relatively young age of the index patients,
speculating that arrhythmias may occur at more advanced
ages and stages of the disease. Interestingly, LGE was related
to genotype positivity in index patients, which is comparable
to another study.30 Our results indicate that positive LGE in
combination with positive genotype may serve for risk
assessment, but the clinical importance of LGE with regard
to arrhythmias in children and adolescents with primary
cardiomyopathies remains to be determined.
The occurrence of adverse events was not related to sex in
our index patients. However, female sex was described as an
independent predictor of all-cause-mortality in adult DCM.40
Worse survival41 and increased disease progression risk to
advanced heart failure or death42 was also found in women
with HCM. Because our pediatric patient cohort is young, one
may speculate that sex-specific endocrine effects possibly
affect the phenotype in adolescence or adulthood and thus
may emerge at continuous follow-up.
The detection rate of >1 VOI was significantly higher in
patients with HTx compared with non-HTx patients. Survival
analysis showed that the probability of adverse events was
significantly higher in patients with >1 VOI compared with
those with 1 or no VOI. This finding agrees with reported
adverse outcomes in pediatric patients with LVNC30,43 and
HCM,44 suggesting that multiple genetic variants may act in a
synergistic manner. The possible underlying mechanisms
most likely depend on the individual disease genes and
respective combination of variants. Whole-exome sequencing
could be a useful tool to identify even more disease-
associated genetic variants.45 Limitations still exist in the
interpretation of genetic variants for ACMG, and in this case,
the targeted-gene panel approach was chosen.46 Neverthe-
less, in this study, many VUSs were detected in the index
patients (24%) and FMs (47%); this result indicates that,
especially in the FMs, many VOIs may not be disease-
associated or may be nonpenetrant.
A significantly higher risk of major adverse events was
found in children with genetic forms of LVNC than in those
with sporadic LVNC.47 Our study consistently showed
reduced event-free survival in genetic cardiomyopathies
compared with sporadic forms; however, the difference did
not reach statistical significance. This finding may be
explained by the comparatively small sample sizes and needs
to be confirmed in larger patient populations.
Limitations
The index patient cohort was heterogeneous and included
different types of primary cardiomyopathies. The relatively
small sizes of the cardiomyopathy subgroups limited in-depth
analysis. Clinical (numeric) data of pediatric patients and
adults cannot be directly compared because different refer-
ence values apply. Therefore, clinical characteristics of
pediatric index patients and FMs were considered separately
in the analysis. The study center offers ultimate therapy for
end-stage heart failure patients, including MCS and HTx. This
may have led to an overrepresentation of patients with severe,
end-stage DCM in this cohort. In addition to pathogenic and
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likely pathogenic variants, VUSs were also defined as VOIs.
This approach may have led to overestimation of genetic
versus sporadic cardiomyopathies because these variants
have not yet been confirmed as disease causing and might be
reclassified in the future as benign as other genomic data
sets become available. Age-related disease progression is
possibly not fully covered within the reported study
period. Consequently, long-term follow-up examinations are
required to further assess risk stratification of pediatric
cardiomyopathies.
Conclusions
Systematic phenotype and genotype characterization provides
important prognostic information about children and adoles-
cents with cardiomyopathies and their first-degree FMs.
Lower BSA, increased NT-proBNP, LV dysfunction and dilata-
tion, LGE, and increased number of VOIs were associated with
adverse outcome and should be used for stratified risk
assessment in pediatric primary cardiomyopathies. Family
screening suggests a large load of uncertain genetic variants
in FMs or possibly nonpenetrance of pathogenic variants,
which needs more long-term follow-up to verify.
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 Table S1. List of bioinformatically filtered cardiomyopathy genes. 
Gene name Gene Protein Chromosome Transcript ID Exons 
ATP binding cassette 
subfamily C member 9 
ABCC9 ABCC9 Chr12 ENST00000261200.8, NM_020297 
ENST00000261201.8, NM_005691 
38 
actin, alpha 1, skeletal muscle ACTA1 ACTA1 Chr1 ENST00000366684.7, NM_001100 6 
actin, alpha, cardiac muscle 1 ACTC1 ACTC1 Chr15 ENST00000290378.4, NM_005159.4  7 
actinin alpha 2 ACTN2 ACTN2 Chr1 ENST00000366578.5, NM_001103.2  21 
Alstrom syndrome protein 1  ALMS1 ALMS1 Chr2 ENST00000613296.4, NM_015120.4  23 
ankyrin repeat domain 1 ANKRD1 ANKRD1 Chr10 ENST00000371697.3, NM_014391.2  9 
BCL2 associated athanogene 3 BAG3 BAG3 Chr10 ENST00000369085.7, NM_004281.3 4 
B-Raf proto-oncogene, 
serine/threonine kinase 
BRAF BRAF Chr7 ENST00000288602.10, NM_004333.4 18 
calreticulin 3 CALR3 CALR3 Chr19 ENST00000269881.7, NM_145046 9 
caveolin 3 CAV3 CAV3 Chr3 ENST00000343849.2, NM_033337 2 
CBL proto-oncogene CBL CBL Chr11 ENST00000264033.5, NM_005188.3 16 
cytochrome c oxidase 
assembly homolog 
COX15 COX15 Chr10 ENST00000370483.9, NM_001320975 9 
crystallin alpha B CRYAB CRYAB, 
HSPB5 
Chr11 ENST00000616970.4, NM_001885.1  4 
cysteine and glycine rich 
protein 3 
CSRP3 CSRP3 Chr11 ENST00000533783.1, NM_003476 7 
desmin DES DES Chr2 ENST00000373960.3, NM_001927.3 9 
dystrophin DMD DMD ChrX ENST00000357033.8, NM_004006.2  79 
DnaJ heat shock protein 
family (Hsp40) member C19 
DNAJC19 DNAJC19, 
TIM14 
Chr3 ENST00000382564.6, NM_145261 6 
dolichol kinase DOLK DOLK Chr9 ENST00000372586.3, NM_014908 1 
desmocollin 2 DSC2 DSC2 Chr18 ENST00000280904.10, NM_024422 16 
desmoglein 2 DSG2 DSG2 Chr18 ENST00000261590.12, NM_001943.3  15 
desmoplakin DSP DSP Chr6 ENST00000379802.7, NM_004415.2  24 
dystrobrevin alpha DTNA DTNA Chr18 ENST00000444659.5, NM_001390.4 22 
emerin EMD EMD ChrX ENST00000369842.8, NM_000117 6 
EYA transcriptional 
coactivator and phosphatase 4 
EYA4 EYA4 Chr6 ENST00000355167.7, NM_172105.3  20 
fibrillin 1 FBN1 FBN1 Chr15 ENST00000316623.9, NM_000138.4 66 
 four and a half LIM domains 1 FHL1 FHL1 ChrX ENST00000394155.6, NM_001159702.2  8 
four and a half LIM domains 2 FHL2 FHL2 Chr2 ENST00000344213.8, NM_201555.1  7 
fukutin related protein FKRP FKRP Chr19 ENST00000318584.9, NM_001039885 4 
fukutin FKTN FKTN Chr9 ENST00000223528.6, NM_006731 10 
frataxin FXN FXN Chr9 ENST00000377270.7, NM_000144 5 
glucosidase alpha, acid GAA GAA Chr17 ENST00000302262.7, NM_000152 20 
GATA zinc finger domain 
containing 1 
GATAD1 GATAD1 Chr7 ENST00000287957.3, NM_021167 5 
galactosidase alpha GLA GLA ChrX ENST00000218516.3, NM_000169 7 
hydroxyacyl-CoA 
dehydrogenase/3-ketoacyl-
CoA thiolase/enoyl-CoA 
hydratase (trifunctional 
protein), alpha subunit 
HADHA HADHA Chr2 ENST00000380649.7, NM_000182 20 
hyperpolarization activated 
cyclic nucleotide gated 
potassium channel 4 
HCN4 HCN4 Chr15 ENST00000261917.3, NM_005477.2  8 
hemochromatosis  HFE HFE Chr6 ENST00000357618.9, NM_000410.3  5 
HRAS proto-oncogene, 
GTPase 
HRAS HRAS  Chr11 ENST00000610977.3, NM_001130442 5 
heat shock protein 
family B (small) member 8 
HSPB8 HSP22, 
HSPB8 
Chr12 ENST00000281938.6, NM_014365.2 3 
junctophilin-2 JPH2 JPH2 Chr20 ENST00000372980.3, NM_020433.4  6 
junction plakoglobin JUP JUP Chr17 ENST00000393931.7, NM_002230.2  14 
KRAS proto-oncogene, 
GTPase 
KRAS KRAS Chr12 ENST00000311936.7, NM_004985 5 
laminin subunit alpha 2 LAMA2 LAMA2 Chr6 ENST00000421865.2, NM_000426.3 65 
laminin subunit alpha 4 LAMA4 LAMA4 Chr6 ENST00000230538.11, NM_001105206.2 39 
lysosomal associated 
membrane protein 2 
LAMP2 LAMP2, 
CD107b 
ChrX ENST00000434600.6, NM_001122606.1 9 
LIM domain binding 3 LDB3 LDB3 Chr10 ENST00000429277.6, NM_001171610.1  14 
lamin A/C LMNA LMNA Chr1 ENST00000368300.8, NM_170707.3  12 
mitogen-activated protein 
kinase kinase 1 
MAP2K1 MAP2K1, 
MEK1 
Chr15 ENST00000307102.9, NM_002755 11 
mitogen-activated protein 
kinase kinase 2 
MAP2K2 MAP2K2, 
MEK2 
Chr19 ENST00000262948.9, NM_030662 11 
mindbomb E3 ubiquitin 
protein ligase 1 
MIB1 MIB1 Chr18 ENST00000261537.6, NM_020774 21 
myosin binding protein C, 
cardiac 
MYBPC3 MYBPC3 Chr11 ENST00000545968.5, NM_000256.3  35 
 myosin heavy chain 6 MYH6 MYH6, 
MHC-a 
Chr14 ENST00000405093.7, NM_002471.3  39 
myosin heavy chain 7 MYH7 MYH7, 
MHC-b 
Chr14 ENST00000355349.3, NM_000257.2  40 
myosin light chain 2 MYL2 MYL2 Chr12 ENST00000228841.12, NM_000432.3 7 
myosin light chain 3 MYL3 MYL3 Chr3 ENST00000292327.4, NM_000258.2  7 
myosin light chain kinase 2 MYLK2 MYLK2 Chr20 ENST00000375985.4, NM_033118.3  13 
myozenin 2 MYOZ2 MYOZ2 Chr4 ENST00000307128.5, NM_016599.4  6 
myopalladin MYPN MYPN Chr10 ENST00000358913.9, NM_032578 20 
nexilin F-actin binding protein NEXN NEXN Chr1 ENST00000334785.11, NM_144573.3  13 
NK2 homeobox 5 NKX2-5 NKX2-5 Chr5 ENST00000329198.4, NM_004387.3  2 
NRAS proto-oncogene, 
GTPase 
NRAS NRAS Chr1 ENST00000369535.4, NM_002524 7 
PDZ and LIM domain 3 PDLIM3 PDLIM3 Chr4 ENST00000284770.9, NM_014476 7 
plakophilin 2 PKP2 PKP2 Chr12 ENST00000070846.10, NM_004572.3  14 
phospholamban PLN PLN Chr6 ENST00000357525.5, NM_002667 2 
PR/SET domain 16 PRDM16 PRDM16, 
MEL1 
Chr1 ENST00000270722.9, NM_022114.3 17 
protein kinase AMP-activated 
non-catalytic subunit gamma 2 
PRKAG2 PRKAG2 Chr7 ENST00000287878.8, NM_016203.3 16 
protein tyrosine phosphatase, 
non-receptor type 11 
PTPN11 PTPN11 Chr12 ENST00000635625.1, NM_001330437 15 
Raf-1 proto-oncogene, 
serine/threonine kinase 
RAF1 RAF1 Chr3 ENST00000251849.8, NM_002880.3 17 
RNA binding motif protein 20 RBM20 RBM20 Chr10 ENST00000369519.3, NM_001134363.1 14 
ryanodine receptor 2 RYR2 RYR2 Chr1 ENST00000366574.6, NM_001035.2  105 
sodium channel protein type 5 
subunit alpha 
SCN5A SCN5A Chr3 ENST00000413689.5, NM_001099404.1  28 
cytochrome c oxidase 
assembly protein 
SCO2 SCO2 Chr22 ENST00000252785.3, NM_001169111  2 
succinate dehydrogenase 
complex flavoprotein subunit 
A 
SDHA SDHA, 
SDH2 
Chr5 ENST00000264932.10, NM_004168 15 
sarcoglycan beta SGCB SGCB Chr4 ENST00000381431.9, NM_000232.4 6 
sarcoglycan delta SGCD SGCD Chr5 ENST00000435422.7, NM_000337.5  8 
sarcoglycan gamma SGCG SGCG Chr13 ENST00000218867.3, NM_000231 8 
SHOC2, leucine rich repeat 
scaffold protein 
SHOC2 SHOC2 Chr10 ENST00000369452.8, NM_007373.3  9 
 SOS Ras/Rac guanine 
nucleotide exchange factor 1 
SOS1 SOS1 Chr2 ENST00000402219.6, NM_005633.3 23 
tafazzin TAZ TAZ ChrX ENST00000601016.5, NM_000116 11 
T-box 20 TBX20 TBX20 Chr7 ENST00000408931.3, NM_001077653.2  8 
titin-cap, telethonin TCAP TCAP Chr17 ENST00000309889.2, NM_003673 2 
transforming growth factor 
beta 3 
TGFB3 TGFB3 Chr14 ENST00000238682.7, NM_003239.2 7 
transmembrane protein 43 TMEM43 TMEM43 Chr3 ENST00000306077.4, NM_024334.2  12 
troponin C1, slow skeletal and 
cardiac type 
TNNC1                                                                          TNNC1 Chr3 ENST00000232975.7, NM_003280.2 6 
troponin I3, cardiac type TNNI3 TNNI3 Chr19 ENST00000344887.9, NM_000363.4  8 
troponin T2, cardiac type TNNT2 TNNT2 Chr1 ENST00000236918.11, NM_001276345 16 
tropomyosin 1 TPM1 TPM1 Chr15 ENST00000403994.7, NM_001018005.1  9 
titin TTN  titin Chr2 ENST00000589042.5, NM_001267550.1  363 
transthyretin TTR TTR Chr18 ENST00000237014.7 NM_000371.3 4 
vinculin VCL VCL Chr10 ENST00000211998.9, NM_014000.2  22 
 
 
  
 Table S2. Clinical characteristics of index patients. 
 
 
All 
n=60 
DCM 
n=21 
HCM 
n=17 
LVNC 
n=15 
RCM 
n=5 
ARVC 
n=2 
p-
value 
Female 25 (42) 12 (57) 4 (24) 7 (47) 2 (40) 0 (0) 0.215 
Age  
(years) 
7.8 
(4.0-14.4) 
6.8 
(1.0-13.8) 
12.1 
(4.2-16.3) 
7.8 
(4.4-11.7) 
4.2 
(3.3-11.2) 
11.7* 
 
0.450 
 
BSA  
(kg/m²) 
1.0 
(0.5-1.5) 
0.8 
(0.3-1.5) 
1.3 
(0.9-1.9) 
0.8 
(0.4-1.2) 
0.5 
(0.5-1.2) 
1.4* 
 
0.108 
 
NYHA 
I 
II 
III 
IV 
n.a. 
 
37 (62) 
0 (0) 
8 (13) 
2 (3) 
13 (22) 
 
8 (38) 
0 (0) 
4 (19) 
1 (5) 
8 (38) 
 
13 (77) 
0 (0) 
2 (12) 
0 (0) 
2 (12) 
 
12 (80) 
0 (0) 
0 (0) 
0 (0) 
3 (20) 
 
2 (40) 
0 (0) 
2 (40) 
1 (20) 
0 (0) 
 
2 (100) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0.047 
Heart failure signs 17 (28) 9 (43) 0 (0) 4 (27) 4 (80) 0 (0) <0.001 
Arrhythmias† 
SVT 
nsVTs 
 
2 (5) 
5 (12) 
(n=43) 
 
1 (8) 
3 (23) 
(n=13) 
 
0 (0) 
1 (8) 
(n=13) 
 
0 (0) 
1 (8) 
(n=13) 
 
1 (50) 
0 (0) 
(n=2) 
 
0 (0) 
0 (0) 
(n=2) 
0.594 
NT-proBNP  
(pg/ml) 
1496 
(91-9215) 
n=53 
4947 
(123-24841) 
n=21 
1949 
(130-2906) 
n=14 
157 
(69-13488) 
n=11 
2384 
(1659-11030) 
n=5 
12* 
 
n=2 
0.073 
VO2max  
(ml/kg*min) 
33 
(24-40) 
n=24 
23 
(23-40) 
n=5 
32 
(28-39) 
n=11 
39 
(27-41) 
n=6 
13* 
 
n=1 
40* 
 
n=1 
0.337 
Echocardiography  
Z-score LVIDD 
(mm) 
1.6 
(-1.2-4.9) 
n=60 
5.5 
(3.7-9.7) 
n=21 
-0.9 
(-3.2 - -0.1) 
n=17 
1.6 
(-0.2-4.9) 
n=15 
-1.8 
(-2.5 - -1.4) 
n=5 
0.2* 
 
n=2 
<0.001 
Z-Score IVSD  
(mm) 
0.6 
(-0.4-1.9) 
n=59 
-0.4 
(-1.3-1.3) 
n=20 
5.8 
(2.7-15.5) 
n=17 
0.2 
(-0.2-1.0) 
n=15 
-0.4 
(-0.4-0.5) 
n=5 
-0.4* 
 
n=2 
<0.001 
LV-EF  
(%) 
55 
(34-61) 
n=58 
35 
(17-49) 
n=21 
62 
(57-74) 
n=16 
56 
(29-58 
n=15 
61 
(48-70) 
n=5 
62* 
 
n=2 
<0.001 
E/E´ 6.7           
(5.1-9.5) 
n=42 
8.4 
(5.4-13.7) 
n=15 
6.4 
(4.6-12.2) 
n=13 
7.1 
(5.3-9.5) 
n=8 
6.3 
(4.3-8.1) 
n=4 
6.1 
 
n=2 
0.819 
LA 
(cm²) 
11.8 
(7.0-15.7) 
n=51 
12.3 
(5.8-16.3) 
n=18 
11.8 
(10.7-15.2) 
n=16 
11.2 
(6.2-14.0) 
n=10 
15.7 
(9.5-21.9) 
n=5 
9.9 
 
n=2 
0.623 
CMR  
LVEDVi  
(ml/m²) 
95  
(83-122) 
n=28 
124 
(113-224) 
n=11 
86  
(82-91) 
n=8 
93  
(80-98) 
n=6 
87* 
 
n=2 
95* 
 
n=1 
0.014 
LVEF  
(%) 
57  
(46-64) 
n=28 
33  
(14-52) 
n=11 
65  
(61-72) 
n=8 
56  
(53-61) 
n=6 
77* 
 
n=2 
53* 
 
n=1 
0.001 
LA 
(cm²) 
20.3 
(17.6-24.7) 
19.7 
(16.5-26.5) 
22.5 
(18.8-25.1) 
17.8 
(17.0-20.8) 
40.0 
 
21.2 
 
0.266 
 n=26 n=10 n=8 n=6 n=1 n=1 
LGE positive 8 (29) 
n=28 
2 (18) 
n=11 
4 (50) 
n=8 
1 (17) 
n=6 
0 (0) 
n=2 
1 (100 ) 
n=1 
0.230 
 
 
Values are n (%) or median (interquartile range); *only median. †Arrhythmias were recorded 
with Holter-ECG. 
ARVC = arrhythmogenic right ventricular cardiomyopathy; BSA = body surface area; CMR = 
cardiovascular magnetic resonance; DCM = dilated cardiomyopathy; HCM = hypertrophic 
cardiomyopathy; IVSD = interventricular septum thickness at end-diastole; LA = left atrial 
area; LGE = late gadolinium enhancement; LVEDVi = indexed left ventricular enddiastolic 
volume; LVEF = left ventricular ejection fraction; LVIDD = left ventricular internal dimension 
at end-diastole; LVNC = left ventricular noncompaction cardiomyopathy; n.a. = not applicable; 
nsVT = non-sustained ventricular tachycardia; NT-proBNP = N-terminal pro brain natriuretic 
peptide; NYHA = New York Heart Association; RCM = restrictive cardiomyopathy; SVT = 
supraventricular tachycardia; VO2max = maximum oxygen consumption. 
  
 Table S3. Devices and complications of index patients. 
 
All 
n=60 
DCM 
n=21 
HCM 
n=17 
LVNC 
n=15 
RCM 
n=5 
ARVC 
n=2 
p-
value 
MCS       0.004 
LVAD 
BVAD 
ECMO 
9 (15) 
4 (7) 
3 (5) 
7 (33) 
1 (5) 
2 (10) 
0 (0) 
0 (0) 
0 (0) 
2 (13) 
0 (0) 
0 (0) 
0 (0) 
3 (60) 
1 (20) 
0 (0) 
0 (0) 
0 (0) 
 
ICD 6 (10) 1 (5) 5 (29) 0 (0) 0 (0) 0 (0) 0.059 
HTx 16 (27) 9 (43) 0 (0) 3 (20) 4 (80) 0 (0) <0.001 
Death 2 (3) 0 (0) 0 (0) 0 (0) 2 (40) 0 (0) 0.006 
 
Values are n (%). 
ARVC = arrhythmogenic right ventricular cardiomyopathy; BVAD = biventricular assist 
device; DCM = dilated cardiomyopathy; ECMO = extracorporal membrane oxygenation; 
HCM = hypertrophic cardiomyopathy; HTx = heart transplantation; ICD = implantable 
cardioverter-defibrillator; LVAD = left ventricular assist device; LVNC = left ventricular 
noncompaction cardiomyopathy; RCM = restrictive cardiomyopathy. 
 
 Table S4. Characteristics of siblings ≤18 years of age. 
 
Siblings ≤ 18 years 
(n=25) 
Female 13 (52) 
Age 
(years) 
10.6 
(8.7-14.2) 
BSA 
(kg/m²) 
1.1 
(0.9-1.5) 
NYHA 
I 
II 
III 
IV 
n.a. 
 
21 (91) 
0 (0) 
0 (0) 
0 (0) 
2 (9) 
Heart failure signs 
2 (8) 
n=24 
Arrhythmias* 
SVT 
nsVTs 
 
0 (0)  
0 (0) 
n=20 
NT-proBNP 
(pg/ml) 
30 
(16-79) 
n=13 
VO2max 
(ml/kg*min)  
39 
(32-44) 
n=13 
Echocardiography 
Z-score LVIDD 
(mm) 
  0.1 
(-0.7-1.2) 
n=23 
Z-Score IVSD 
(mm) 
-0.2 
(-0.7-1.3) 
n=23 
LVEF  
(%) 
62 
(56-66) 
n=24 
E/E´ 5.3 
(4.6-5.9) 
 
n=14 
LA 
(cm²) 
9.2 
(6.7-11.4) 
n=24 
CMR 
LVEDVi 
(ml/m²) 
86 
(75-94) 
n=9 
LVEF 
(%) 
63 
(57-65) 
n=9 
LA 
(cm²) 
18.3 
(13.1-21.5) 
n=9 
 LGE positive 0 (0) 
n=9 
 
 
Values are n (%) or median (interquartile range). *Arrhythmias were recorded with Holter-ECG. 
BSA = body surface area; CMR = cardiovascular magnetic resonance; IVSD = interventricular septum thickness 
at end-diastole; LA = left atrial area; LGE = late gadolinium enhancement; LVEDVi = indexed left ventricular 
enddiastolic volume; LVEF = left ventricular ejection fraction; LVIDD = left ventricular internal dimension at 
end-diastole; n.a. = not applicable; nsVT = non-sustained ventricular tachycardia; NT-proBNP = N-terminal pro 
brain natriuretic peptide; NYHA = New York Heart Association; SVT = supraventricular tachycardia; VO2max = 
maximum oxygen consumption. 
  
 Table S5. Characteristics of siblings >18 years of age and parents. 
 Siblings >18 years Parents 
 
Female 
(n=4) 
Male 
(n=4) 
Female 
(n=51) 
Male 
(n=40) 
Age  
19.1  
(18.5-20.1) 
20.2  
(18.9-21.2) 
39.3  
(34.4-45.1) 
43.8  
(36.3-49.1) 
BSA 
(kg/m²) 
1.8 
(1.6-1.9) 
 
2.0 
(1.7-2.3) 
 
1.79 
(1.66-1.89) 
n=49 
2.0 
(1.9-2.2) 
n=39 
NYHA  
I 
II 
III 
IV 
 
4 (100) 
0 (0) 
0 (0) 
0 (0) 
 
4 (100) 
0 (0) 
0 (0) 
0 (0) 
 
48 (94) 
3 (6) 
0 (0) 
0 (0) 
 
37 (93) 
3 (8) 
0 (0) 
0 (0) 
Arrhythmias† 
SVT 
nsVT 
 
0 (0) 
0 (0) 
 
 
0 (0) 
0 (0) 
 
 
1 (2) 
2 (5) 
n=44 
 
1 (3) 
2 (6) 
n=36 
NT-proBNP  
(pg/ml) 
88 
(43-104) 
 
36 
(10.4-125.4) 
 
72 
(27-140) 
n=47 
38 
(20-76) 
n=36 
VO2max  
(ml/kg*min) 
31 
(30-35) 
 
33* 
 
n=3 
28 
(24-32) 
n=36 
29 
(24-34) 
n=32 
Echocardiography 
LVIDD 
(mm) 
43 
(40-46) 
 
44 
(37-50) 
 
45 
(42-48) 
n=38 
52 
(46-56) 
n=32 
IVSD  
(mm)  
9 
(7-10) 
 
9 
(8-12) 
 
9 
(7-9) 
n=38 
10 
(8-12) 
n=34 
LVEF  
(%)  
65 
(60-68) 
 
60 
(56-65) 
 
59 
(55-62) 
n=40 
60 
(57-62) 
n=33 
E/E´ 4.6 
 
n=3 
4.3 
 
n=3 
5.3 
(4.8-6.6) 
n=29 
5.8 
(4.7-7.6) 
n=26 
LA 
(cm²) 
13.2 
 
n=3 
12.0 
(10.2-20.1) 
n=4 
12.1 
(10.3-13.4) 
n=40 
12.7 
(10.7-17.3) 
n=34 
CMR 
LVEDVi 
(ml/m²) 
79 
(74-92) 
 
84* 
 
n=2 
76 
(69-84) 
n=36 
85 
(77-98) 
n=29 
LVEF 
(%) 
64 
(60-64 
 
66* 
 
n=2 
62 
(60-65) 
n=36 
61 
(56-65) 
n=29 
LA 
(cm²) 
18.1 
(17.0-23.6) 
n=4 
19.0 
 
n=2 
20.2 
(17.2-23.0) 
n=36 
22.0 
(20.0-26.6) 
n=29 
LGE positive 0 (0) 
 
0 (0) 
n=2 
2 (6) 
n=33 
2 (7) 
n=27 
  
Values are n (%) or median (interquartile range); *only median. †Arrhythmias were recorded with 
Holter-ECG. 
Echocardiographic and CMR data are given for females and males to account for sex-specific reference 
values.  
BSA = body surface area; CMR = cardiovascular magnetic resonance; IVSD = interventricular septum 
diastolic diameter; LA = left atrial area; LGE = late gadolinium enhancement; LVEDVi = indexed left 
ventricular enddiastolic volume; LVEF = left ventricular ejection fraction; LVIDD = left ventricular 
internal dimension at end-diastole; nsVT = non-sustained ventricular tachycardia; NT proBNP = N 
terminal pro brain natriuretic peptide; NYHA = New York Heart Association; SVT = supraventricular 
tachycardia; VO2max = maximum oxygen consumption. 
 
  
 Figure S1. Classification of genetic results. 
 
Data were analysed according to genotype positivity, grade of pathogenicity and number of variants of 
interest (VOI). VUS = variants of unknown significance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
